FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and aims at treating macular degeneration in a mammal. A pharmaceutical composition for treating macular degeneration in a mammal contains an effective amount of 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2α isopropyl ester. The above ophthalmic composition is presented in the form of eye drops, which are sterile, preservative-free as a single-use dosage form. What is also provided is a method of treating macular degeneration in a mammal that involves administering an effective amount of 13,14-dihydro-15-keto-20-ethyl-prostaglandin F2α isopropyl ester into an individual in need thereof.
EFFECT: using declared group of inventions provides effective treatment of macular degeneration in a mammal.
11 cl, 1 tbl, 2 dwg, 2 ex
